Jack Bendheim, President and CEO of Phibro Animal Health Corporation (NASDAQ:PAHC), disclosed the indirect sale of 18,608 shares of Common Stock across multiple open-market transactions from May 5, 2026 through May 7, 2026, as reported in the SEC Form 4 filing.
Transaction summary
Metric | Value
|
|---|
Shares sold (indirect) | 18,608 |
Transaction value | $1.0 million
|
Post-transaction shares (direct) | 16,840 |
Post-transaction shares (indirect) | 56,152 |
Post-transaction value (direct ownership) | ~$727K |
Transaction value based on SEC Form 4 weighted average purchase price ($54.61); post-transaction value based on total reported shares multiplied by the final May 7, 2026 close price, as calculated in SEC data.
Key questions
How material was the reduction in indirect ownership from this sale?
This sale accounted for 24.89% of Jack Bendheim’s indirect holdings, reducing his indirect position via BFI Co. LLC from 74,760 shares to 56,152 shares as of May 7, 2026.
What trading plan governed these transactions?
These sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on December 11, 2025
How do these trades compare to Bendheim’s historical activity?
Since January 2026, trade sizes have remained within the typical historical range for Bendheim, with the most recent sales reflecting a reduction in capacity as total reported holdings fell by 96.77% from 520,712 to 16,840 shares over the “recent” period.
Does Bendheim maintain a material ownership stake after this transaction?
Despite this disposition, Bendheim continues to have exposure through 16,840 directly held shares, 56,152 shares held indirectly, and a total of 449,485 Class A Common Stock shares (direct and indirect), which are convertible into Common Stock, preserving meaningful economic alignment.
Company overview
Metric | Value |
|---|
Revenue (TTM) | $1.50 billion |
Net income (TTM) | $95.23 million |
Dividend yield | 1.88% |
1-year price change | 50.21% |
* 1-year performance calculated using May 7th, 2026 as the reference date.
Company snapshot
PAHC produces and markets animal health products, nutritional specialties, vaccines, and mineral nutrition solutions for livestock, including poultry, swine, cattle, and aquaculture.
The company generates revenue primarily through the sale of proprietary and generic pharmaceuticals, nutritional additives, and specialty ingredients to the commercial animal agriculture sector.
It serves integrated poultry, swine, and cattle producers, as well as animal feed manufacturers, wholesalers, and distributors across the United States and international markets.
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products, serving livestock producers in the United States and international markets. The company leverages a broad distribution network and technical expertise to address the evolving needs of commercial food animal producers. Its product portfolio includes specialty pharmaceuticals and nutritional solutions for the animal health industry.
What this transaction means for investors
Pre-scheduled sales carry less signal than discretionary selling since the timing factor is taken out of the equation. What does add context is that Bendheim set up the plan in December 2025 — the same month Phibro announced he’d be stepping back from the CEO role to become Executive Chairman, with his son Daniel taking over on July 1, 2026. That’s a natural moment for a founder-era executive to begin trimming a position he’s built over decades. Bendheim has been with the company since 1969 and has run it as President since 1988 — the kind of tenure that makes a planned, gradual wind-down of direct holdings fairly unremarkable. The more relevant question heading into the transition is whether Daniel Bendheim, who has been inside the business since 1997, can sustain the momentum from Phibro’s recent acquisition of a Zoetis medicated feed additive portfolio and keep margin expansion on track. That integration, not this filing, is where investors should be focused.
Should you buy stock in Phibro Animal Health right now?
Before you buy stock in Phibro Animal Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Phibro Animal Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $477,813!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,320,088!*
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 208% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 23, 2026.
Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Phibro’s CEO transition puts this insider sale in context was originally published by The Motley Fool
